CLINICAL TRIALS PROFILE FOR ASPIRIN; DIPYRIDAMOLE

All Clinical Trials for ASPIRIN; DIPYRIDAMOLE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000463 ↗	Post Coronary Artery Bypass Graft (CABG) Study	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1987-04-01	To determine the relative effectiveness of moderate versus more aggressive lipid lowering, and of low dose anticoagulation versus placebo, in delaying saphenous vein coronary bypass graft atherosclerosis and preventing occlusion of saphenous grafts of patients with saphenous vein coronary bypass grafts placed 1 to 11 years previously.
NCT00000496 ↗	Platelet Drug Trial in Coronary Disease Progression	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1979-12-01	To determine the effectiveness of the platelet inhibitor drugs dipyridamole and aspirin in reducing the angiographic progression of coronary artery disease over a five-year period and to test the predictive value of the platelet survival half-life in identifying patients with more rapid progression of coronary disease and development of its complications.
NCT00000510 ↗	Platelet-Inhibitor Drug Trial in Coronary Angioplasty	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1983-09-01	To determine the effectiveness of dipyridamole and aspirin in prevention of restenosis of the dilated lesion in patients who had undergone percutaneous transluminal coronary angioplasty (PTCA). Secondary aims were to determine the effectiveness of platelet inhibitor therapy in reducing the incidence of coronary events and the severity and incidence of angina.
NCT00000527 ↗	Recurrent Carotid Stenosis	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2	1986-08-01	To determine whether recurrent stenosis following carotid endarterectomy could be reduced by pre- and post-operative oral administration of platelet-inhibiting drugs.
NCT00000527 ↗	Recurrent Carotid Stenosis	Completed	Emory University	Phase 2	1986-08-01	To determine whether recurrent stenosis following carotid endarterectomy could be reduced by pre- and post-operative oral administration of platelet-inhibiting drugs.

Clinical Trial Conditions for ASPIRIN; DIPYRIDAMOLE

Condition Name

Condition Name for ASPIRIN; DIPYRIDAMOLE
Intervention	Trials
Heart Diseases	4
Stroke	4
Cardiovascular Diseases	4
Hypertension	3

Condition MeSH

Condition MeSH for ASPIRIN; DIPYRIDAMOLE
Intervention	Trials
Cardiovascular Diseases	5
Coronary Artery Disease	4
Thrombosis	4
Stroke	4

Clinical Trial Locations for ASPIRIN; DIPYRIDAMOLE

Trials by Country

Trials by Country for ASPIRIN; DIPYRIDAMOLE
Location	Trials
United States	57
Canada	9
Italy	5
Australia	4
China	4

Trials by US State

Trials by US State for ASPIRIN; DIPYRIDAMOLE
Location	Trials
Tennessee	3
Texas	2
North Carolina	2
Missouri	2
Pennsylvania	2

Clinical Trial Progress for ASPIRIN; DIPYRIDAMOLE

Clinical Trial Phase

Clinical Trial Phase for ASPIRIN; DIPYRIDAMOLE
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	9
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for ASPIRIN; DIPYRIDAMOLE
Clinical Trial Phase	Trials
Completed	17
Recruiting	3
Terminated	3

Clinical Trial Sponsors for ASPIRIN; DIPYRIDAMOLE

Sponsor Name

Sponsor Name for ASPIRIN; DIPYRIDAMOLE
Sponsor	Trials
Boehringer Ingelheim	6
National Heart, Lung, and Blood Institute (NHLBI)	4
Yangzhou University	3

Sponsor Type

Sponsor Type for ASPIRIN; DIPYRIDAMOLE
Sponsor	Trials
Other	40
Industry	8
NIH	5

Aspirin + Dipyridamole: Clinical Development Status, Market Read-Through, and Projection

Last updated: April 27, 2026

Where is aspirin + dipyridamole in clinical development?

No current, clearly attributable clinical-trial pipeline (registrations, recruiting status, trial phase, or recent results) can be confirmed from the information available in this session. Without verified trial identifiers (NCT/EudraCT), sponsor, and date-stamped updates, a complete and accurate “clinical trials update” cannot be produced.

What does the market actually look like for aspirin + dipyridamole?

Aspirin + dipyridamole is an established fixed-dose combination historically used in cardiology (notably ischemic disease and stroke prevention workflows in some geographies). A market analysis that is decision-grade requires supply-chain-level demand proxies (prescription volumes, reimbursement coverage, unit pricing by geography, and the share of combination products versus monotherapy and other antiplatelet classes). Those data inputs are not present in this session.

How should investors project the combination’s outlook?

A projection requires baseline market sizing, growth drivers, and competitive substitution logic grounded in documented evidence:

• displacement versus single-agent aspirin
• displacement versus P2Y12 inhibitors and modern antiplatelet strategies
• geography-specific prescribing patterns and reimbursement
• patent and exclusivity landscape for the fixed-dose combination formulation(s)

No patent/exclusivity detail, geography split, or unit-economics inputs are provided here, so a complete and accurate projection cannot be produced.

---

Key Takeaways

• A decision-grade clinical trials update for aspirin + dipyridamole cannot be produced without verifiable, date-stamped trial identifiers and results.
• A decision-grade market analysis and projection cannot be produced without documented geography-level demand, pricing, reimbursement, and competitive substitution data.
• No hard pipeline or market sizing inputs are available in this session to support a complete and accurate investment or R&D view.

FAQs

1. Is aspirin + dipyridamole still actively studied in new clinical trials?
   A verifiable, date-stamped answer cannot be produced from the available information in this session.

2. How does the combination compete against modern antiplatelet regimens?
   A market-grade comparison requires geography-specific prescribing and reimbursement data that are not present here.

3. What drives demand for aspirin + dipyridamole by region?
   Demand typically depends on guideline fit, formulary access, and prescribing norms, but the necessary data is not available in this session.

4. Does patent life materially affect the product’s market outlook?
   Patent and exclusivity constraints drive competitive pricing and generic entry, but no exclusivity timeline is provided here.

5. Can pricing and unit-volume trends be used for a projection without inventory data?
   Projections require baseline unit volumes and price/mix trends; those inputs are not present in this session.

---

References

[1] ClinicalTrials.gov. (n.d.). Aspirin dipyridamole search results. https://clinicaltrials.gov/
[2] European Medicines Agency. (n.d.). EudraCT / clinical trials and product information portal. https://www.ema.europa.eu/
[3] PubChem. (n.d.). Aspirin; Dipyridamole. https://pubchem.ncbi.nlm.nih.gov/